These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3195198)

  • 1. Enhancement of field stability and utility of future biologicals through prior accelerated degradation testing.
    Arya SC
    Vaccine; 1988 Oct; 6(5):386. PubMed ID: 3195198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization and control of biologicals produced by recombinant DNA technology. Proceedings of a symposium, Geneva, Switzerland, 29 Nov.-1 Dec. 1983.
    Dev Biol Stand; 1985; 59():1-209. PubMed ID: 4007270
    [No Abstract]   [Full Text] [Related]  

  • 3. USDA licensing policy for biologicals produced by R-DNA.
    Espeseth DA; Shibley GP; Joseph PL; van Deusen RA; Whetstone CA
    Dev Biol Stand; 1985; 59():167-73. PubMed ID: 4007275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality control of biologicals produced by recombinant DNA techniques. WHO consultation.
    WHO Consultation
    Bull World Health Organ; 1983; 61(6):897-911. PubMed ID: 6609009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody.
    Mayer A; Chester KA; Bhatia J; Pedley RB; Read DA; Boxer GM; Begent RH
    Eur J Cancer; 1998 Jun; 34(7):968-76. PubMed ID: 9849442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfection and transformation of human and animal cells by recombinant DNA vectors: issues relevant to use of these substrates for the production of biologicals.
    Moyer MP; Moyer RC
    Dev Biol Stand; 1989; 70():91-100. PubMed ID: 2547678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern science for better quality control of medicinal products "Towards global harmonization of 3Rs in biologicals": The report of an EPAA workshop.
    Schutte K; Szczepanska A; Halder M; Cussler K; Sauer UG; Stirling C; Uhlrich S; Wilk-Zasadna I; John D; Bopst M; Garbe J; Glansbeek HL; Levis R; Serreyn PJ; Smith D; Stickings P
    Biologicals; 2017 Jul; 48():55-65. PubMed ID: 28596049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of guidelines for field testing of plants modified by recombinant DNA techniques.
    Milewski E; Tolin SA
    Recomb DNA Tech Bull; 1984 Sep; 7(3):114-24. PubMed ID: 6595719
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on license requirements and veterinary biologicals.
    Baker LR
    J Am Vet Med Assoc; 1972 Feb; 160(4):509-10. PubMed ID: 5030605
    [No Abstract]   [Full Text] [Related]  

  • 13. Considerations regarding the development of individual nonclinical test strategies in the European Community.
    Günzel P; Bass R
    Hum Exp Toxicol; 1991 Sep; 10(5):297-304. PubMed ID: 1683541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of a gene recombinant: what does it mean and how to check for it?
    Galibert F
    Biologicals; 1990 Jul; 18(3):221-4. PubMed ID: 2257135
    [No Abstract]   [Full Text] [Related]  

  • 16. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of the individual and the community in the research, development, and use of biologicals with criteria for guidelines: a memorandum.
    Bull World Health Organ; 1976; 54(6):645-55. PubMed ID: 1088511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA: let the public choose.
    Wright S
    Nature; 1978 Oct; 275(5680):468. PubMed ID: 692727
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
    Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
    J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.